<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393389</url>
  </required_header>
  <id_info>
    <org_study_id>Acotec-07</org_study_id>
    <nct_id>NCT04393389</nct_id>
  </id_info>
  <brief_title>Acotec DCB Post Market Clinical Follow-up</brief_title>
  <acronym>FLOWER</acronym>
  <official_title>All Comers Post Market Clinical Follow-up to Continue the Surveillance of the Acotec Drug Coated PTA Catheter Orchid, Tulip and Litos in Lower Limb Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acotec Scientific Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acotec Scientific Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All-comers, prospective, multi-center, single-arm, non-interventional post market clinical
      follow-up (PMCF) Cohort 1 - Claudicants: Rutherford Clinical Category (RCC) 2-3 Cohort 2 -
      Critical Limb Ischemia: Rutherford Clinical Category (RCC) 4-6
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To prospectively collect and assess safety and efficacy data on the AcoArt drug-coated PTA
      balloon catheters carrying the CE Mark per current Instructions for Use in a real-world
      cohort of patients with symptomatic arterial disease undergoing endovascular lower limb
      revascularization per the institution's standard practice.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 4, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy endpoint - non-CLI group</measure>
    <time_frame>12 Months</time_frame>
    <description>Freedom from clinically-driven target lesion revascularization (CD-TLR) within 12 months after index procedure, which is defined as any re-intervention within the target lesion(s) due to recurrent clinical symptoms of PAD (increase of one Rutherford class or more) and/or drop of ankle-brachial index (≥20% or &gt;0.15 when compared with maximum early post-procedural level).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary efficacy endpoint -CLI group</measure>
    <time_frame>6 Months</time_frame>
    <description>Freedom from clinically-driven TLR within 6 months after index procedure, which is defined as any re-intervention within the target lesion(s) due to delayed or worsening wound healing, new or recurrent wound, or worsening Rutherford class.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint- non-CLI group</measure>
    <time_frame>30 days</time_frame>
    <description>A composite of freedom from major adverse limb events and perioperative death (MALE-POD) through 30 days after index procedure. A major adverse limb event is defined as above-ankle amputation or major reintervention (ie, new bypass graft, major surgical graft revision such as a jump graft or an interposition graft, or thrombectomy/thrombolysis) of the treated limb.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint- CLI group</measure>
    <time_frame>12 Months</time_frame>
    <description>A composite of freedom from device- and procedure-related mortality, freedom from major target limb amputation and TLR within 12 months post-index procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Any TLR (including clinically-driven and incidental TLR)</measure>
    <time_frame>6 months,12 months,24 months, 36months,48 months,60 months</time_frame>
    <description>Any TLR (including clinically-driven and incidental TLR) at 6,12, 24, 36, 48, 60 months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Target vessel revascularization (TVR)</measure>
    <time_frame>6 months,12 months,24 months, 36months,48 months,60 months</time_frame>
    <description>Target vessel revascularization (TVR) at 6, 12, 24, 36, 48, 60 months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Target limb revascularization</measure>
    <time_frame>6 months,12 months,24 months, 36months,48 months,60 months</time_frame>
    <description>Target limb revascularization at 6, 12, 24, 36, 48, 60 months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CD-TLR</measure>
    <time_frame>6 months,12 months,24 months, 36months,48 months,60 months</time_frame>
    <description>CD-TLR at 6, 24, 36, 48, 60 months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All-cause mortality</measure>
    <time_frame>6 months,12 months,24 months, 36months,48 months,60months</time_frame>
    <description>All-cause mortality at 6, 12, 24, 36, 48, 60 months post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Device- or procedure-related death</measure>
    <time_frame>30 days, 6 months</time_frame>
    <description>Device- or procedure-related death at 30 days and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Major amputation</measure>
    <time_frame>6 months,12 months,24 months, 36months,48 months,60 months</time_frame>
    <description>Major amputation at 6, 12, 24, 36, 48, 60 months post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Technical success</measure>
    <time_frame>Post procedure</time_frame>
    <description>Technical success defined as final in-lesion residual diameter stenosis ≤50% by angiographic visual estimate at the end of the index procedure without device malfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Procedural success</measure>
    <time_frame>Post procedure</time_frame>
    <description>Procedural success defined as technical success without procedural complications (death, major target limb amputation, thrombosis of the target lesion, or CD-TLR) prior to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rutherford clinical category (target limb)</measure>
    <time_frame>6 months,12 months,24 months, 36months,48 months,60 months</time_frame>
    <description>Changes in Rutherford clinical category (target limb) at 6, 12, 24, 36, 48, 60 months post-procedure compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of primary sustained clinical improvement</measure>
    <time_frame>6 months,12 months,24 months, 36months,48 months,60 months</time_frame>
    <description>Primary sustained clinical improvement, defined as improvement in Rutherford classification by one or more categories compared with baseline, without TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of secondary sustained clinical improvement</measure>
    <time_frame>6 months,12 months,24 months, 36months,48 months,60 months</time_frame>
    <description>Secondary sustained clinical improvement, defined as improvement in Rutherford classification by one or more categories compared with baseline, including patients with TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of (Major) Amputation-free survival - CLI group</measure>
    <time_frame>6 months,12 months,24 months, 36months,48 months,60 months</time_frame>
    <description>(Major) Amputation-free survival at 6, 12, 24, 36, 48, 60 months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Minor amputation - CLI group</measure>
    <time_frame>6 months,12 months,24 months, 36months,48 months,60 months</time_frame>
    <description>Minor amputation at 6, 12, 24, 36, 48, 60 months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Wound healing - CLI group</measure>
    <time_frame>60 months</time_frame>
    <description>healed or not; if not, improving, stagnant,worsening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New or recurrent wound of the target limb - CLI group</measure>
    <time_frame>60 months</time_frame>
    <description>New or recurrent wound of the target limb</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>non-CLI group</arm_group_label>
    <description>Rutherford Clinical Category (RCC) 2-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLI group</arm_group_label>
    <description>critical limb ischemia，Rutherford Clinical Category (RCC) 4-6</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcoArt Orchid (0.035&quot;), AcoArt Tulip (0.018&quot;) and AcoArt Litos (0.014&quot;) percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd.</intervention_name>
    <description>All comers Post Market Clinical Follow-up to continue the surveillance of the Acotec Drug Coated PTA Catheter AcoArt Orchid, AcoArt Tulip and AcoArt Litos in lower limb treatment</description>
    <arm_group_label>CLI group</arm_group_label>
    <arm_group_label>non-CLI group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with symptomatic arterial disease undergoing endovascular lower limb
        revascularization per the institution's standard practice.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Patient is ≥ 18 years old at the time of consent.

          -  2. Significant stenosis (≥70%) or occlusions of de-novo or restenotic lesion(s)
             located in iliac, superficial femoral, popliteal and/or infra-popliteal arteries
             suitable for angioplasty per operator visual assessment.

          -  3. Lesion(s) can be treated with available AcoArt Orchid (0.035&quot;), AcoArt Tulip
             (0.018&quot;) and AcoArt Litos (0.014&quot;) DCB device per current IFU.

          -  4. Subject has provided written informed consent prior to participation in the PMCF,
             understands the purpose of this PMCF and agrees to comply with all protocol-specified
             examinations and follow-up appointments.

          -  5. Rutherford Classification Category 2-6 Subjects with Rutherford Category 2 have
             gone through a conservative therapy without success.

          -  6. Inflow lesion treated prior to target lesion treatment

        Exclusion Criteria:

          -  1. Rutherford Classification Category 0, 1

          -  2. Patient already enrolled in other investigational (interventional) studies that
             would interfere with study endpoints

          -  3. Inability to tolerate required antithrombotic or antiplatelet therapies.

          -  4. Non-dilatable severely calcified lesion.

          -  5. Known hypersensitivity/allergy to components of the investigational device

          -  6. Un-treated acute or subacute thrombus in the target lesion.

          -  7. Life expectancy &lt; 1 year.

          -  8. Pregnancy or female patient with child bearing potential not taking adequate
             contraceptives or currently lactating.

          -  9. Other comorbidities, which in the opinion of the investigator limit longevity or
             likelihood of compliance with protocol follow up.

          -  10. Myocardial infarction or stroke within 30 days prior to index procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scheinert Dierk</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Angiology, University Hospital Leipzig,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scheinert Dierk</last_name>
    <phone>+49-341-97</phone>
    <phone_ext>18770</phone_ext>
    <email>dierk.scheinert@medizin.uni-leipzig.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Angiology, University Hospital Leipzig,</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Scheinert Dierk</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

